Saturday, April 24, 2010

Seattle biotech firm on verge of a groundbreaking cancer vaccine

Bob Feutz, 84, a retired Boeing manager, at his Redmond home with some of his photography. Bob participated in clinical trials of Provenge, a prostate cancer vaccine, developed by Seattle-based Dendreon, that is poised to be the first approved cancer vaccine in the U.S. His cancer has not come back or spread.